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ASSOCIATION OF MALAT1 RS3200401 GENE 
POLYMORPHISM WITH KIDNEY CANCER IN UKRAINIAN 
POPULATION. 
 
Introduction. As it is known, only 2 % of the human genome en-
codes proteins, while the greater part of the genome corresponds to non-
coding sequences. In the recent years among a large variety of non-
coding sequences special attention of researchers was drawn to long non-
coding RNA MALAT1. This sequence first was detected in 2003 in non-
small cell lung cancer cells. Today the results of numerous experiments 
revealed that MALAT1 is one of the major genes involved in various 
types of cancer, including kidney cancer.  
Purpose. To study the association between MALAT1 rs3200401 po-
lymorphism and kidney cancer development in Ukrainian population. 
Materials and methods. 101 patients with kidney cancer (renal cell 
carcinoma) was enrolled into the study. The final diagnosis was based on 
anamnesis data, clinical, biochemical and instrumental examinations 
according to the recommendations of European Association of Urology. 
All participants were treated in the hospital of Sumy Regional Oncology 
Center. The control group included 100 healthy individuals without per-
sonal cancer history. The study of MALAT1 rs3200401 SNP was 
perfprmed by Real-time PCR using 7500 Fast Real-time PCR System 
(Applied Biosystems, Foster City, USA) and Taq-Man Assays (Taq-
Man®SNP Assay C_3246069_10). Statistical analyses were performed 
using Statistical Package for Social Science software (SPSS, version 
17.0, Chicago, IL, USA) and online resource “SNIPKA”. 
Results. The distribution of CC-homozygotes, CT-heterozygotes and 
TT-homozygotes in patients with kidney cancer was 71 (70.3%), 29 
(28.7 %) and 1 (0.99 %), respectively. In the control group, distribution 
of genotypes was 59 (59.0 %), 32 (32.0 %) and 9 (9.0 %), respectively. 
The significant difference in genotypes distribution between kidney can-
cer patients and the control group was found (P = 0.022). Genotypic 
analysis has shown that T-minor allele carriers had less risk of kidney 
cancer development compared to patients with CC-genotype (P = 0.031, 
OR = 0.101, 95 % CI = 0.013–0.814). 
Conclusion. There is statistically significant link between MALAT1 
rs3200401 polymorphism and kidney cancer development in Ukrainian 
population. Individuals with minor T-allele (TT- and CT-genotypes) 
have less risk of renal cell carcinoma development compared to major 
homozygotes (CC).  
Keywords: MALAT1, long non coding RNA, single nucleotide pol-
ymorphism, renal cell carcinoma. 
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ЗВ’ЯЗОК ПОЛІМОРФІЗМУ RS3200401 ГЕНУ MALAT1 
З РАКОМ НИРКИ В УКРАЇНСЬКІЙ ПОПУЛЯЦІЇ.  
  
Наведено результати вивчення поліморфізму rs3200401 гену 
MALAT1 у 101 хворого на рак нирки та 100 осіб контрольної 
групи. Виявлено статистично значиму різницю у розподілі гено-
типів за поліморфізмом rs3200401 гену MALAT1 у пацієнтів з 
раком нирки та осіб без цієї недуги. У носіїв мінорного алелю 
(генотипи Т/Т та С/Т) за поліморфізмом rs3200401 гену MALAT1 
ризик розвитку раку нирки менший у порівнянні з домінантними 
гомозиготами (С/С). Мінорний алель (T) є протективним . 
Ключові слова: MALAT1, довга некодуюча РНК, однонуклео-
тидний поліморфізм, рак нирки.  
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Introduction 
Today more and more scientific articles report 
about various transcripts that do not encode amino 
acid sequences. In humans, about 20,000 genes 
encoding proteins have been detected. These genes 
presenting no more than 2% of the whole genome. 
Wherein almost 90% of our genome is actively 
transcribed. Thus, most of transcripts are 
represented by non-coding RNAs that regulate the 
expression of more than 70% human genes [1]. 
The non-coding RNA molecules, depending on 
their length, are divided into short (less than 200 
nucleotides) and long (more than 200 nucleotides). 
While the influence of short versions of these 
molecules, especially miRNAs, on cancer 
development by inhibiting of RNA expression has 
already been described, the effect of long non-
coding RNAs is less clear [2]. 
Particular attention is paid to MALAT1 
transcript (metastasis associated lung 
adenocarcinoma transcript), also known as 
NEAT2 (noncoding nuclear-enriched abundant 
transcript 2), which belongs to class of long non-
coding RNA [3]. MALAT1 gene was firstly 
identified in 2003 in non-small cell lung cancer 
cells, which had the high level of MALAT1 
expression [4]. Numerous publications shown the 
link between MALAT1 expression and various 
types of cancer development including 
endometrial cancer, breast cancer, cervical cancer, 
colorectal cancer, hepatocellular carcinoma, liver 
cancer, neuroblastoma, osteosarcoma, pancreatic 
cancer, prostate cancer, bladder cancer, stomach 
cancer, undifferentiated embryonic liver sarcoma 
and lung cancer [5]. Rare cases of chromosomal 
translocation involving MALAT1 have been 
reported in kidney carcinoma cells [6]. Along with 
this, studies about association of MALAT1 gene 
polymorphisms with kidney cancer development 
are absent both in Ukrainian population and in 
other populations and ethnic groups of the world.  
Objective. To study the association between 
MALAT1 rs3200401 gene polymorphism and 
kidney cancer development in Ukrainian 
population. 
Materials and methods. The study was 
conducted using venous blood of 101 kidney 
cancer (renal cell carcinoma) patients. The final 
diagnosis was established on the basis of 
anamnesis, clinical, biochemical and instrumental 
methods data in accordance with European 
Association of Urologists (EAU) 
recommendations. The control group consisted of 
100 clinically healthy donors who had no 
oncological diseases in history. 
The research was carried out in compliance 
with the basic provisions of Convention on Human 
Rights and Biomedicine, Declaration of Helsinki 
of the World Medical Association (1964, with 
subsequent amendments, including version 2000) 
and the Order of the Ministry of Health of Ukraine 
No. 690 dated 23.09. 2009. All participants signed 
an informed consent to participate in studies with 
subsequent venous blood using for genetic 
analysis. 
Determination of MALAT1 rs3200401 gene 
polymorphism was carried out by real time 
polymerase chain reaction (Real-Time PCR) 
method using the TaqMan®SNP Assay 
C_3246069_10 components. Amplification mode: 
primary denaturation – 20 s at 95°C, denaturation 
– 30 s at 95°C, annealing with elongation – 
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P = 0.016 
30 seconds at 60°C (only 50 cycles). The 
amplification and results analysis were carried out 
using 7500 Fast Real-Time PCR System (Applied 
Biosystems, Foster City, USA) and 7500 Fast 
Real-time PCR Software. 
Statistical data processing was performed using 
SPSS 17.0 software package and “SNIPKA” online 
resource (https://thething.shinyapps.io/SNPcalc). 
P < 0.05 was considered as significant. 
Results. The distribution of rs3200401 
genotypes in renal cell carcinoma patients and 
control group individuals corresponded to Hardy-
Weinberg equilibrium (Table 1). 
Table 1 –  Frequency of MALAT1 rs3200401 gene polymorphism alleles and genotypes in case and control 
groups 
 Case Control 
Homozygotes СС, n (%) 71 (70.3) 59 (59) 
Heterozygotes СТ, n (%) 29 (28.7) 32 (32) 
Homozygotes ТТ, n (%) 1 (1) 9 (9) 
С-allele 0.85 0.75 
Т-allele 0.15 0.25 
χ2 1,12 2.15 
P > 0.05 > 0.05 
Note: n is the number of patients, χ2 and P represent the deviations of each group from Hardy-Weinberg 
equilibrium 
Among kidney cancer patients the number of 
main allele homozygotes (CC) was 71 (70.3%), 
heterozygotes (CT) – 29 (28.7%), recessive allele 
homozygotes (TT) – 1 (1%). In control group the 
distribution of genotypes was as follows: main 
allele homozygotes (CC) – 59 (59%), heterozy-
gotes (CT) – 32 (32%), minor homozygotes – 9 
(9%). The alleles frequency was also calculated. 
In the case group the frequency of main and minor 
alleles was 0.85 and 0.15, respectively. In the con-
trol group the main allele frequency was 0.75, the 
minor allele frequency – 0.25. Comparative analy-
sis showed that difference in genotypes distribu-
tion and alleles frequencies between two groups is 
statistically significant (P = 0.022 and P = 0.016, 
respectively) (Figure 1). 
 
 
 
 
 
Figure 1 – Comparison of rs3200401 genotypes (A) and alleles (B) frequencies in main (dark columns) and 
control (light column) groups 
 
In order to determine the risk of kidney cancer 
development depending on rs3200401 genotypes, 
the odds ratio (OR) and 95% confidence interval 
(CI) for the four main models of inheritance were 
calculated (Table 2). Recessive model had the 
lowest Aikaike index. According to this, the minor 
allele carriers (CT- and TT-genotypes) have the 
lower kidney cancer risk (P = 0.031, OR = 0.101, 
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95% CI = 0.013-0.814) compared to CC-
homozygotes. 
Discussion. MALAT1 is highly conserved 
long non-coding RNA, which firstly was 
associated with lung tumors with high metastasis 
propensity [4]. MALAT1 gene is located on 
11q13.1 and consists of 8,829 nucleotides 
(according to genecards.org). According to the 
base of single-nucleotide polymorphisms (dbSNP) 
there are 5558 single nucleotide polymorphisms 
within MALAT1 gene [7]. 
MALAT1 gene is often associated with various 
tumors development. Hai-min Zhang et al.  
revealed that MALAT1 transcript expression 
correlates with size, stage of tumors and 
metastases in lymph nodes in patients with lung 
cancer. No reliable association with distant 
metastases was detected. It was also found that 
among patients with high MALAT1 gene 
expression 16 had tumor size less than 4 cm and 
30 had tumor size greater or equal to 4 cm. Among 
patients with low MALAT1 expression 49 had 
tumor size less than 4cm, and 11 patients had 
tumor size greater or equal to 4 cm [8]. 
Table 2 – Analysis of MALAT1 rs3200401 gene polymorphism association with kidney cancer under different 
models of inheritance 
Model P OR (95% CI) AIC 
Dominant 0.095 0.608 (0.339-1.090) 21.58 
Recessive 0.031 0.101 (0.013-0.814) 16.61 
Overdominant 0.612 0.856 (0.469-1.563) 24.14 
Additive
1
 
0.362 
0.026 
0.753 (0.409-1.386) 
0.092 (0.011-0.750) 
17.78 
Note: 95% CI – 95% confidence interval; OR – odds ratio; AIC – Akaike Information Criterion. 
1
The first line in additive model describes comparison of CT-genotype with CC-genotype, the second line – 
comparison of TT-genotype with CC-genotype  
 
The genotyping of lung cancer patients for 
MALAT1 rs3200401 polymorphism was performed 
by Wang et al. It was found that patients with TT- 
and CT-genotypes had significantly higher 
average life expectancy compared to homozygotes 
CC. Authors concluded T-allele is linked to longer 
life expectancy among patients with lung cancer 
[11]. Peng et al., studying the effects of several 
MALAT1 gene polymorphisms on breast cancer 
development, found that rs3200401 heterozygotes 
(CT) had lower breast cancer risk compared to 
dominant homozygotes (CC) [12]. 
Our results revealed the statistically significant 
association between MALAT1 rs3200401 gene 
polymorphism and kidney cancer development. It 
has been established that T-allele is protective, 
and T-allele carriers (CT and TT genotypes) have 
lower risk of kidney cancer development 
compared to homozygotes CC. 
In recent years the role of long non-coding 
RNAs, in particular MALAT1, in cardiovascular 
diseases pathogenesis was actively studied. Qian 
Li et al. studied the association of MALAT1 gene 
polymorphisms with congenital heart diseases 
development in Chinese population. Scientists 
have established the significant association 
between rs619586 polymorphism and risk of 
congenital heart diseases development. According 
to dominant model of inheritance patients with 
AG- and GG-genotypes had significantly lower 
congenital heart diseases risk compared to 
individuals with AA-genotype. Newborns with 
rs619586 GG-genotype also had a lower risk of 
congenital heart diseases development. The 
protective effect of this SNP under additive model 
was also significant. Wherein significant 
association between rs11227209, rs3200401 
polymorphisms and congenital heart defects 
development was not detected [9]. Wang et al. 
demonstrated that rs619586G-allele is protective 
against coronary arteriosclerosis. Also statistical 
analysis showed that coronary artery 
atherosclerosis patients with rs11227209G-, 
rs619586G- and rs3200401T-alleles have lower 
total cholesterol level [10]. 
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Conclusions  
1. There is the link between MALAT1 
rs3200401 gene polymorphism and kidney cancer 
development in Ukrainian population. 
2. The carriers of MALAT1 rs3200401 gene 
polymorphism minor allele (genotype TT and CT) 
have the less risk of renal cell carcinoma develop-
ment compared to homozygotes CC. 
 
Prospects for further research 
Today is shown that MALAT1 gene and its 
polymorphisms are associated with many types 
of oncological processes. Therefore, our further 
research will be aimed at detecting the associa-
tion of rs3200401 SNP with other types of onco-
logical nosologies. 
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